In-Vivo CAR-T
From Concept to Clinic – What It Will Take to Win the “Age of In-Vivo”
Peter Robinson, MBA, Director Therapeutic Strategy, Novotech
In-vivo CAR-T therapy offers a scalable alternative to ex-vivo approaches by engineering immune cells directly inside the body. This article explores the scientific advances, clinical progress, and regulatory strategies driving the “Age of In-Vivo,” and what it will take for this emerging modality to deliver on its transformative potential for patients.
For the past decade, ex-vivo CAR-T therapies have set a new bar for clinical impact in hematologic malignancies. Yet their own success story exposes the limits of the model: intensive apheresis, bespoke manufacturing, narrow site networks, high costs, and long vein-to-vein times that too often disqualify or delay patients. In-vivo CAR-T, the ability to engineer therapeutic cells directly inside the body, aims to rewrite those constraints. If it delivers on its promise, in-vivo CAR platforms could merge the potency of autologous cell therapy with the scalability of traditional biologics, expanding access, bending cost curves, and accelerating time to treatment.
Momentum is real. Capital is flowing into viral and non-viral delivery platforms; big-pharma partnerships have validated multiple approaches; and a first wave of clinical trials is underway across oncology and autoimmune indications. But the path from elegant mechanism to reliable medicine will turn on a familiar triad: precise targeting and dosing, predictable safety, and scalable, regulator-ready execution.
This byline synthesises where the field stands and what it will take to reach durable clinical and commercial adoption.
Why In-Vivo, and Why Now?
The core limitation of ex-vivo CAR-T therapy is not biological; it is logistical. Autologous constructs are effective but require individualised cell collection, ex-vivo manipulation, and fit-for-release testing for every patient. Allogeneic products promise off-the-shelf convenience, yet potentially introduce higher risks of graft-versus-host reactions, immune rejection, and scale-up challenges.
In-vivo CAR approaches invert the model: deliver genetic instructions to the right cell population within the patient and allow biology to handle manufacturing. Whether using targeted lentiviral particles, adenoviral or AAV vectors, mRNA-lipid nanoparticles, or hybrid nanocarriers, the goal is consistent: program, expand, and sustain therapeutic effector cells in situ.
If successful, this model could resemble a single-dose or redosable biologic rather than a bespoke product, unlocking broader access and faster treatment initiation.
Recent regulatory approvals of TIL, TCR, and next-generation CAR-T therapies in solid tumors and autoimmune conditions have normalised advanced cellular modalities across agencies and payers, creating a favorable environment for in-vivo CAR innovation.
The Platform Race: Targeting, Kinetics, and Control
Vectors and nanocarriers are the fulcrum of in-vivo CAR development. Across platforms, three engineering questions dominate:
Cellular specificity. Most early programs focus on T-cell targeting (CD3, CD4/CD8, or CD19-directed), but the field is expanding into myeloid, NK, macrophage, and Treg populations. The challenge remains balancing efficient tropism with minimising off-target effects.
Expression durability. Integrating vectors (lentiviral, transposon-based) support long-term CAR expression but require close insertional safety monitoring. Non-integrating systems (AAV, mRNA-LNPs) favor modularity and redose potential but need repeated dosing for durable activity. Hybrid strategies are emerging, using transient expression to establish safety before durable integration.
On-demand control. Future differentiation will hinge on controllability, including drug-gated CARs, safety switches, titratable promoters, and dosing strategies that give clinicians finer control of activity and safety.
What the First Clinical Wave Is Teaching Us
Early-stage clinical programs are distributed across diverse technologies: lentiviral systems for durable T-cell reprogramming, mRNA-LNP approaches prioritizing redosability, and AAV variants optimized for T-cell selectivity.
Key lessons so far include:
• Speed to pharmacology matters. In oncology, especially in relapsed or refractory settings, rapid in-vivo generation of functional effector cells can be critical. Non-human primate data showing rapid B-cell aplasia with CD19 constructs are encouraging, pending confirmation in humans.
• Safety profiles may differ by indication. Autoimmune indications may tolerate in-vivo CARs with fewer severe cytokine-related events than oncology, though vector-related immune responses and reactogenicity remain important considerations. Emerging phenomena such as Local Immune Cell-Associated Toxicity Syndrome (LICATS) highlight the need for specialised centres and predefined management algorithms.
Regulatory Strategy: Global, Harmonised, and Data-Rich
In-vivo CAR therapies occupy a regulatory landscape adjacent to gene therapy, allowing developers to leverage established precedents while addressing novel vector-specific issues.
Key focus areas include:
Translationally relevant preclinical models. Immunocompetent, humanised, and non-human primate studies should be used to clarify biodistribution, immune memory, and vector persistence.
Early agency interaction. Pre-IND and scientific advice meetings help align expectations on vector tropism, insertional mutagenesis, and long-term follow-up.
Long-term safety frameworks. Whether using integrating or non-integrating systems, robust monitoring for persistence, replication-competent virus, and clonal evolution is essential.
Solid Tumors and Beyond: Designing for the Hard Mode
Hematologic cancers remain the fastest path to validation, but solid tumors and autoimmune diseases represent the true test of the in-vivo model. Success will require combining vector engineering with tumor- or tissue-specific strategies:
Trafficking and infiltration. Approaches such as chemokine receptor engineering, stromal modulation, and oncolytic virus combinations can improve tumor access.
Antigen heterogeneity. Multi-specific and logic-gated CARs, or “one cell, multiple CAR” designs, may mitigate antigen escape.
Autoimmune and fibrotic applications. Goals include deep depletion of pathogenic cells, durable immune reset, and functional recovery without chronic immunosuppression.
Five Design Principles for Next-Generation Programs
Start with the clinic, not the vector. Let indication biology drive platform selection.
Design trials for real-world relevance. Capture time-to-treat, infusion logistics, and patient resource use.
Treat CMC as a clinical variable. Analytical precision directly impacts safety and comparability.
Plan globally. Harmonise early with major regulatory regions to streamline later development. Use regions like Australia to accelerate first-in-human trials while preparing harmonised data packages for the FDA and EMA, and other key markets such as China.
The Outlook: Coexistence, Not Replacement
In-vivo CAR-T therapies are not replacements for autologous or allogeneic ex-vivo models but valuable complements. Each approach will serve distinct clinical and logistical niches: autologous constructs for personalised therapy, allogeneic for off-the-shelf use, and in-vivo systems for scalable, rapid intervention.
The promise is clear: engineer immune cells directly where they reside, eliminate the slowest steps, and give clinicians tools to modulate therapy dynamically. The scientific foundation is strong; the next phase will test whether precision, safety, and durability can converge to make in-vivo CAR-T a reliable therapeutic reality.
Author Bio
Peter Robinson, MBA, Director Therapeutic Strategy, Novotech. He is a Clinical Operations and Development Leader with more than 20 years of experience in CRO and biotech settings. His focus is on advancing cell and gene therapy programs from concept to clinic, with a passion for improving patient access to transformative treatments.
